Epratuzumab
Modify Date: 2025-08-25 12:25:06
Epratuzumab structure
|
Common Name | Epratuzumab | ||
|---|---|---|---|---|
| CAS Number | 205923-57-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of EpratuzumabEpratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases[1]. |
| Name | Lymphocide |
|---|
| Description | Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Epratuzumab binds to CD22 ECD on Biacore with a KD of 0.7 nM, and resulting CD22 phosphorylation[1].Epratuzumab (0-100 μM; 1h) results in a dose dependent increase in CD22 internalization in Daudi lymphoma cells[1]. |
| References |
| No Any Chemical & Physical Properties |